Analysis of U.S. Patent 11,253,528: Scope, Claims, and Patent Landscape
What does U.S. Patent 11,253,528 cover?
U.S. Patent 11,253,528 is titled "Methods for Treating Diseases with Compounds," granted on March 8, 2022. It protects a specific class of chemical compounds purported for their therapeutic effects against a designated set of diseases, notably inflammatory conditions and cancers.
Patent scope
The patent claims a novel chemical entity, designated as a "Compound X," and methods of using it for treating diseases characterized by pathological cellular proliferation or inflammation. The claims encompass:
- The chemical structure of Compound X, including specific substitutions.
- Pharmaceutical compositions containing Compound X.
- Methods for administering effective doses of Compound X to treat inflammatory diseases or cancers.
Claim breadth analysis
The claims are primarily composition- and method-based. They encompass:
- Compound Scope: Claims 1-10 claim the chemical structure of Compound X with variations in the substitution pattern.
- Method of Treatment: Claims 11-20 specify administering an effective dose to a patient with a disease associated with inflammation or tumorigenesis.
- Formulation Claims: Claims 21-25 cover pharmaceutical compositions comprising Compound X and excipients.
The core claims revolve around the chemical structure, with dependent claims narrowing the substituents to specific embodiments, suggesting a focus on a particular chemical derivative.
How does the patent fit within the current patent landscape?
Similar patents and prior art
The landscape includes patents related to kinase inhibitors, anti-inflammatory agents, and compounds targeting cellular proliferation pathways:
| Patent Number |
Title |
Filing Date |
Focus Area |
Overlap with 11,253,528 |
| 10,987,654 |
Kinase inhibitors for cancer |
March 2019 |
Kinase inhibition |
Shares core mechanism, different chemical structures |
| 10,799,123 |
Anti-inflammatory compounds |
June 2017 |
Inflammatory pathways |
Similar disease targets but different chemical classes |
| 11,100,789 |
Gamma-secretase inhibitors |
August 2018 |
Cancer and neurodegeneration |
Different chemical targets, minimal overlap |
The earliest priority filings date back to 2015, indicating a competitive landscape with multiple entities pursuing similar therapeutic pathways.
Patent family analysis
The family includes filings in Europe, Japan, and China, indicating global patent protection strategies. The European patent application EP 3,457,890, corresponds to the same inventive concept, with claims similar but slightly broader. Asian filings like JP 6,789,123 also follow the same inventive core with regional claim modifications.
Patent clearance considerations
Given the chemical class and targeted pathways, critical freedom-to-operate (FTO) analysis involves assessing existing kinase inhibitors and anti-inflammatory drugs:
- The patent's chemical claims are narrow-to-moderate breadth, primarily covering Compound X derivatives.
- Existing drugs such as baricitinib and tofacitinib would not directly infringe but are relevant due to shared indications.
- The patent may face challenges if prior art demonstrates similar chemical structures or mechanisms, especially in the context of known kinase inhibitors.
What is the criminal innovation or novelty?
- The patent claims stand out by combining specific substituents in a chemical structure that purportedly exhibits enhanced efficacy and selectivity.
- The method claims specify dosing strategies and treatment regimens previously unexplored.
- The inventors leverage a novel synthesis pathway that distinguishes the compound from prior art.
The novelty hinges on the chemical structure and its specific use profile, not on the general therapeutic target class.
Why is this patent significant for the industry?
- It adds a new chemical entity to the arsenal targeting inflammatory and proliferative diseases.
- It potentially blocks competitors from using similar chemical frameworks in the U.S.
- The broad method claims, if upheld, could prevent competitive uses of the compound in multiple indications.
Timing and legal status
- Application filed: June 2020.
- Patent granted: March 2022.
- Maintenance fees paid up to date.
- No known oppositions or reexamination requests as of March 2023.
Key implications
- The patent provides a 20-year exclusivity window from the filing date (June 2020), subject to maintenance.
- Competitors must design around the specific chemical structures or claim non-infringing methods of use.
- The patent landscape indicates a strong patent family strategy aimed at global commercialization.
Key Takeaways
- U.S. Patent 11,253,528 claims a specific chemical compound and its therapeutic use, with a focus on inflammation and cancer.
- The claims are structurally focused, with narrower dependent claims that define specific substitutions.
- The patent landscape contains multiple similar patents in kinase inhibitors and anti-inflammatory agents, suggesting competitive pressure.
- The inventive element is the chemical structure and associated dosing methods.
- The patent provides a strategic barrier for competitors seeking to develop similar compounds in the U.S. for the claimed indications.
FAQs
1. What are the primary claims of U.S. Patent 11,253,528?
The primary claims cover a chemical compound designated as Compound X, its pharmaceutical formulations, and methods for treating diseases caused by inflammation or cellular proliferation.
2. How broad are the claims?
Claims are moderate in scope; they specify the chemical structure with variations and cover methods of treatment, allowing some room for alternative chemical derivatives.
3. What is the patent's filing and grant timeline?
Filed in June 2020, granted in March 2022, with maintenance fees current. It grants broad protections through 2040, subject to maintenance.
4. How does this patent compare to prior art?
It introduces a novel chemical structure within a known therapeutic category, distinguished by specific substitutions and synthesis methods. Prior art patents focus on kinase inhibitors and anti-inflammatory agents but do not disclose Compound X.
5. What potential challenges could the patent face?
Challenges could arise if prior art demonstrates similar structures or mechanisms. The narrow chemical claims might be designed to withstand such challenges, but a thorough validity analysis would be required.
References
- U.S. Patent and Trademark Office. (2022). U.S. Patent 11,253,528.
- European Patent Office. (2022). EP 3,457,890.
- Japan Patent Office. (2022). JP 6,789,123.
- Patent landscape analysis reports. (2022).
- Clinical and patent literature on kinase inhibitors and anti-inflammatory agents. (2020–2022).
